Loading patent…
AssigneesBeijing Wehand-Bio Pharmaceutical Co., Ltd, Guangxi Wehand-Bio Pharmaceutical Co., Ltd
InventorsYuling LIU, Jun YE, Dongdong LIU, Hongliang WANG, Mo WANG, Renjie LI, Yanfang YANG
Estimating the term…
The invention discloses a use of a mulberry (Morus alba L.) extract, including a method for treating ulcerative colitis, a method for preventing ulcerative colitis, and a method for reduction in Disease Activity Index, DAI. The use is application of a mulberry extract to the preparation of a product for treating and/or preventing ulcerative colitis. The invention experimentally demonstrated that positive drug group, SZ-A-1, SZ-A-2, SZ-A-3, SZ-A-4 and SZ-A-5 (pretreatment) could each significantly inhibit colonic atrophy in UC model mice, and the effects in SZ-A-2, SZ-A-3 and SZ-A-4 groups are comparable to that in positive drug group, with SZ-A-5 (pretreatment) achieving a superior effect to the positive drug. The mulberry extract of the invention, as a component derived from natural plants, has unique advantages of small toxic and side effects, mild and lasting actions etc.
A method for treating ulcerative colitis in a subject, comprising administering a mulberry extract or a main active ingredient thereof to the subject.
A method for preventing ulcerative colitis in a subject, comprising administrating a mulberry extract or a main active ingredient thereof to the subject.
A method for reduction in Disease Activity Index, DAI, for a patient with ulcerative colitis, comprising administrating a mulberry extract or a main active ingredient thereof to the patient.
Dependencies are inferred from the claim text.